{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:47:18Z","timestamp":1793713638494,"version":"4.6.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":645,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2015]]},"DOI":"10.1038\/mtm.2015.31","type":"journal-article","created":{"date-parts":[[2015,9,30]],"date-time":"2015-09-30T10:43:05Z","timestamp":1443609785000},"page":"15031","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["A phase 1 study of a heterologous prime-boost vaccination involving a truncated HER2 sequence in patients with HER2-expressing breast cancer"],"prefix":"10.1016","volume":"2","author":[{"given":"Sung-Bae","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hee","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeongeun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Hae","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mtm.2015.31_bib1","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/319226a0","article-title":"The neu oncogene encodes an epidermal growth factor receptor-related protein","volume":"319","author":"Bargmann","year":"1986","journal-title":"Nature"},{"key":"10.1038\/mtm.2015.31_bib2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1038\/mtm.2015.31_bib3","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.juro.2010.04.077","article-title":"Her-2\/neu expression in prostate adenocarcinoma: a systematic review and meta-analysis","volume":"184","author":"Neto","year":"2010","journal-title":"J Urol"},{"key":"10.1038\/mtm.2015.31_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/GCO.0b013e3283324114","article-title":"Use of monoclonal antibodies in the treatment of ovarian cancer","volume":"22","author":"Mabuchi","year":"2010","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1038\/mtm.2015.31_bib5","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.critrevonc.2009.11.003","article-title":"Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib","volume":"75","author":"Tomasello","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1038\/mtm.2015.31_bib6","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"10.1038\/mtm.2015.31_bib7","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","article-title":"Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease","volume":"17","author":"Cobleigh","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1038\/mtm.2015.31_bib8","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s00262-008-0540-3","article-title":"The E75 HER2\/neu peptide vaccine","volume":"57","author":"Mittendorf","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1038\/mtm.2015.31_bib9","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1089\/hum.1995.6.10-1265","article-title":"Transient expression of genes transferred in vivo into heart using first-generation adenoviral vectors: role of the immune response","volume":"6","author":"Gilgenkrantz","year":"1995","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mtm.2015.31_bib10","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines2030624","article-title":"Developments in viral vector- based vaccines","volume":"2","author":"Takehiro","year":"2014","journal-title":"Vaccines"},{"key":"10.1038\/mtm.2015.31_bib11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.it.2003.11.009","article-title":"Jump-starting the immune system: prime-boosting comes of age","volume":"25","author":"Woodland","year":"2004","journal-title":"Trends Immunol"},{"key":"10.1038\/mtm.2015.31_bib12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ijc.20232","article-title":"Enhanced efficacy of DNA vaccination against Her-2\/neu tumor antigen by genetic adjuvants","volume":"111","author":"Chang","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1038\/mtm.2015.31_bib13","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/gt.2008.81","article-title":"Immunogenicity and safety profiles of genetic vaccines against human Her-2\/neu in cynomolgus monkeys","volume":"15","author":"Ko","year":"2008","journal-title":"Gene Ther"},{"key":"10.1038\/mtm.2015.31_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.breast.2003.09.002","article-title":"Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer","volume":"13","author":"Suter","year":"2004","journal-title":"Breast"},{"key":"10.1038\/mtm.2015.31_bib15","first-page":"639","article-title":"A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells","volume":"6","author":"Lin","year":"1991","journal-title":"Oncogene"},{"key":"10.1038\/mtm.2015.31_bib16","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/S0021-9258(18)52354-1","article-title":"The extracellular domain of p185\/neu is released from the surface of human breast carcinoma cells, SK-BR-3","volume":"266","author":"Zabrecky","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1038\/mtm.2015.31_bib17","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1479-5876-11-62","article-title":"Phase 1 studies of the safety and immunogenicity of electroporated HER2\/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors","volume":"11","author":"Diaz","year":"2013","journal-title":"J Transl Med"},{"key":"10.1038\/mtm.2015.31_bib18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/01.cji.0000165353.19171.41","article-title":"Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer","volume":"28","author":"Miller","year":"2005","journal-title":"J Immunother"},{"key":"10.1038\/mtm.2015.31_bib19","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/sj.bjc.6690343","article-title":"Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2\/neu-overexpressing metastatic breast cancer","volume":"81","author":"Tokuda","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1038\/mtm.2015.31_bib20","doi-asserted-by":"crossref","first-page":"e12873","DOI":"10.1371\/journal.pone.0012873","article-title":"Safety and immunogenicity study of multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa","volume":"5","author":"Walter","year":"2010","journal-title":"PloS One"},{"key":"10.1038\/mtm.2015.31_bib21","first-page":"2782","article-title":"Safety and immunogenicity of a DNA vaccine encoding carcinoemvryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients","volume":"8","author":"Conry","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mtm.2015.31_bib22","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1349-7006.2009.01416.x","article-title":"Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer","volume":"101","author":"Miyazawa","year":"2010","journal-title":"Cancer Sci"},{"key":"10.1038\/mtm.2015.31_bib23","doi-asserted-by":"crossref","first-page":"7477","DOI":"10.1158\/0008-5472.CAN-06-4639","article-title":"A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model","volume":"67","author":"Ko","year":"2007","journal-title":"Cancer Res"},{"key":"10.1038\/mtm.2015.31_bib24","first-page":"521","volume":"21","author":"Lee","year":"2003","journal-title":"Comparison of the antitumor efficacies of Her-2\/neu DNA vaccines inducing contrasting IgG immunity but comparable CTL activity in mice. Vaccine"},{"key":"10.1038\/mtm.2015.31_bib25","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1073\/pnas.93.3.1320","article-title":"Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome","volume":"93","author":"Makimura","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mtm.2015.31_bib26","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s00262-010-0875-4","article-title":"Response definition criteria for ELISPOT assays revisited","volume":"59","author":"Moodie","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"10.1038\/mtm.2015.31_bib27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jim.2004.09.012","article-title":"Development and validation of ELISA for herceptin detection in human serum","volume":"295","author":"Maple","year":"2004","journal-title":"J Immunol Methods"},{"key":"10.1038\/mtm.2015.31_bib28","first-page":"179","article-title":"In vivo properties of three human HER2\/neu-expressing murine cell lines in immunocompetent mice","volume":"49","author":"Penichet","year":"1999","journal-title":"Lab Anim Sci"}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050116300432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050116300432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T09:40:10Z","timestamp":1653212410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050116300432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":28,"alternative-id":["S2329050116300432"],"URL":"https:\/\/doi.org\/10.1038\/mtm.2015.31","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]},"article-number":"15031"}}